Introduction {#sec1}
============

The first cases of COVID-19 were identified in New York State (NYS) in early March, 2020, and since then NYS, particularly the metropolitan New York City (NYC) area, has become one of the most-impacted communities in the United States \[[@bib1],[@bib2]\]. As of June 2, 2020, over 370,000 laboratory-confirmed diagnoses have been made, accounting for approximately 25% of diagnoses in the United States \[[@bib2],[@bib3]\]. As with most infections, laboratory-confirmed diagnoses undercount the true population-level burden of infections; with SARS-CoV-2, the virus that causes COVID-19, key factors that contribute to underdiagnosis include absent or mild symptoms and access to testing \[[@bib4]\]. Thus, although NYS has tested more residents for COVID-19 than any other state (over 2,229,000 persons tested through June 2, 2020), it is likely that laboratory-confirmed cases represent a relatively small portion of the total number of persons with a history of infection in NYS \[[@bib3]\].

Estimates of COVID-19 cumulative incidence (i.e., prevalence of previous or current infection) can inform the extent of epidemic spread and the number of persons still susceptible and progress toward herd immunity, which are critical for parameterizing simulation models and informing policies, including those for altering societal restrictions \[[@bib5]\]. Furthermore, such data provide needed denominators for understanding the extent of diagnosis, rates of hospitalization, morbidity, and mortality, and geographic differences.

Antibody testing for SARS-CoV-2 has emerged as an important tool for understanding infection history. Although a several-week window period for development of IgG antibodies and evidence that not all persons with infection develop an antibody response limit their utility for diagnostics, and their interpretation for short- and long-term immunity remain uncertain, as with other infections, antibody prevalence serostudies with validated assays can assess population-level cumulative incidence in the recent past \[[@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11]\].

Antibody serostudies for SARS-CoV-2 are being conducted in other countries and in the United States are occurring on the national and county levels, but none have been conducted at the state level, and only one population-based serostudy has been peer-reviewed \[[@bib12], [@bib13], [@bib14], [@bib15]\]. The current array of recommendations against individual movement and business operation during the pandemic complicates study specimen collection. A recent RNA survey in Iceland and serosurveys in two California counties conducted sampling at centralized testing sites, which offer ease of execution particularly in small geographies, with potentially large self-selection biases \[[@bib13],[@bib15],[@bib16]\]. Alternative approaches include random at-home mail-in testing and community-intercept studies in high-traffic locations that remain open \[[@bib14]\].

To provide a statewide picture of COVID-19 infection through late-March and diagnoses by early-April 2020, during April 19--28, 2020, the NYS Department of Health (NYSDOH) conducted a community-based serostudy throughout NYS. Cumulative incidence among non-institutionalized adults, by geographic and demographic features, was estimated from weighted reactivity rates that were adjusted for validated test characteristics. Combining these findings with cumulative diagnoses enabled estimation of the percent of infections diagnosed.

Methods {#sec2}
=======

Field study {#sec2.1}
-----------

The NYSDOH conducted a convenience sample of over 15,000 New Yorkers attending 99 grocery stores across 26 counties, which contain 87.3% of the state\'s population, located in all regions of NYS ([Fig. 1](#fig1){ref-type="fig"} ). Grocery stores were chosen as the testing venue because they were classified an essential business to remain open and, due to the necessity of grocery shopping, they attract a heterogeneous clientele \[[@bib17]\]. Store locations were chosen to increase sample coverage of the racial and ethnic diversity of the statewide population.Fig. 1New York State counties included in the New York State Department of Health Serological Testing Survey^1^. ^1^Sampled counties---Long Island: Nassau, Suffolk; New York City: Boroughs of Bronx, Brooklyn, Manhattan, Queens, Staten Island; Westchester, Rockland Counties; Rest of State: Albany, Broome, Clinton, Dutchess, Erie, Greene, Jefferson, Monroe, Niagara, Oneida, Onondaga, Oswego, Rensselaer, Saratoga, Schenectady, Tompkins, and Ulster.

Testing occurred over 6 distinct days from April 19, 2020 through April 28, 2020. Each store had a team of 6--8 staff responsible for recruiting participants, collecting specimens, recording data, and managing specimen transport to Wadsworth Center Laboratory (Albany, NY) for analysis. Eligible subjects were adults aged 18 years or older, New York residents irrespective of county, recruited through a recruitment flyer posted at stores and by systematically approaching each patron as they entered the store. To minimize selection bias, community testing site locations were not announced ahead of time and were changed frequently (i.e., 99 venues in 6 days). Most locations were used only once, and no individual site was used more than twice. Testing was halted at locations that became publicized on social media.

Patrons were given information about the testing, and if interested, completed written informed consent. Procedures included a brief demographic questionnaire and dried blood spot (DBS) collection by trained personnel. Approximately 13% of participants initially had missing demographic data. Staff attempted to capture these data through \>2500 follow-up phone calls, reaching all but approximately 75 participants, who were subsequently excluded from analyses. Test results were delivered to participants by text message if nonreactive and by phone if indeterminant or reactive.

Testing approach {#sec2.2}
----------------

Blood was collected by fingerstick onto custom 903 filter paper cards labeled with a specimen ID. Cards were dried for 3--4 hours at ambient temperature and transported to the Wadsworth Center. A fully saturated greater than or equal to 3-mm-diameter DBS was required. A total of 525 DBS cards from eligible individuals were rejected; 433 with insufficient or improperly collected blood, 92 with no specimen ID. Acceptable DBS cards were processed for testing.

SARS-CoV IgG testing was conducted using a microsphere immunoassay developed and validated for DBS by the NYSDOH Wadsworth Center. Briefly, nucleocapsid (N) antigen-coupled magnetic beads were incubated with blood eluted from a 3-mm DBS punch. Phycoerythrin-labeled goat anti-human IgG secondary antibody was used to detect microsphere-bound IgG antibodies, and the median fluorescence intensity (MFI) was determined using a FlexMap 3D (Luminex Corp., Austin, TX). The mean MFI of 90--100 negative DBS was used to set cutoffs; results greater than the mean MFI plus 6 SDs were reported as reactive; results less than the mean MFI + 3 SDs were nonreactive, and results between the mean MFI +3 to +6 were indeterminate. Serosurvey testing was initiated with SARS-CoV IgG v1, which used SARS-CoV-1N antigen (Wadsworth Center, Albany, NY) and was completed using SARS-CoV IgG v2, which used SARS-CoV-2N protein (Sino Biological, Wayne, PA) after validation studies confirmed comparable performance.

Assay validation studies are described in [Table 1](#tbls1){ref-type="table"}, [Table 2](#tbls2){ref-type="table"}, [Table 3](#tbls3){ref-type="table"}, [Table 4](#tbls4){ref-type="table"}, [Table 5](#tbls5){ref-type="table"} and [Supplementary Figure 1](#figs1){ref-type="fig"}. Specificity was estimated as 99.75%, based on two studies of DBS collected before December 2019 that found 99.5% (95% confidence interval \[CI\]: 98.5%--100%) and 100% (95% CI: 96.1%--100%) specificity. Serum collected from individuals diagnosed with non--COVID-19 respiratory and nonrespiratory agents were tested to assess cross-reactivity; only 1 of 85 samples was reactive. Of 232 SARS-CoV-2 PCR-positive DBS collected, a median of 35 days after the symptom onset, 204 (87.9%, 95% CI: \[83.7%--92.1%\]) were reactive, informing sensitivity and thus incorporating both test performance and the proportion of infected persons who never develop IgG \[[@bib6],[@bib7]\].

Analysis {#sec2.3}
--------

We estimated SARS-Cov-2 cumulative incidence from observed antibody reactivity using two sequential steps: (1) poststratification weighting to standardize to the NYS population and (2) adjustment by estimated antibody test characteristics.

Using the National Center for Health Statistics bridged-race file, weights were assigned to each participant based on their membership in each of 160 strata of sex, race, and ethnicity (Hispanic, non-Hispanic white, non-Hispanic black, non-Hispanic Asian, and non-Hispanic other), age (18--34, 35--44, 45--54, ≥55 years), and residential region (NYC, Westchester/Rockland, Long Island, Rest of State \[ROS\]) \[[@bib18]\]. Poststratification weights were defined as the proportion each stratum is represented in the state\'s population divided by the analogous proportion in the sample \[[@bib19],[@bib20]\]. Next, we computed weighted frequencies for the percent reactive statewide, with one-way stratifications by sex, race and ethnicity, age group, and region and two-way stratifications within levels of region, including 95% CIs, with differences assessed using Rao-Scott *χ* ^2^ tests \[[@bib21]\]. Indeterminate results were assumed nonreactive, and statistical procedures were two-sided at α = 0.05.

In the second step, weighted reactivity estimates ($p_{reactive}$) and their 95% CI bounds were corrected for test sensitivity and specificity, based on validation data, to yield cumulative incidence, per Bayes\' Rule as applied to the diagnostic 2 × 2 table: $cumulative\ incidence = \frac{p_{reactive} + specificity - 1}{sensitivity + specificity - 1}$ \[[@bib13],[@bib22]\]. Primary analyses used the sensitivity and specificity point estimates from the validation studies, with sensitivity analyses at the extremes of test characteristics\' 95% CI (\[96.1% specificity, 92.1% sensitivity\], \[100% specificity, 83.7% sensitivity\]). Test characteristic--adjusted cumulative incidence values were multiplied by the one- and two-way noninstitutionalized adult populations (e.g., excluding settings such as prisons and nursing homes) from the American Community Survey 2014--2018 Public Use Microdata Sample file \[[@bib23]\]. This yielded the estimated total 'infection-experienced' adults with SARS-CoV-2 within each stratum. With a study midpoint of April 23, and literature estimates of mean 4 days from infection to the symptom onset and mean 21 days from the onset to IgG detection, results represent cumulative incidence through approximately March 29 \[[@bib6],[@bib8],[@bib24]\].

In NYS, diagnostic testing for SARS-CoV-2 is mandatorily reported electronically to the NYSDOH. Using cumulative diagnoses reported and the total numbers of infection-experienced adults, we estimated the percent of infections diagnosed overall and by region, sex, and age. For primary analyses, we accumulated diagnoses through April 9, based on the March 29 final infection date, 4 days to the symptom onset, and mean 7 days from the onset to diagnosis. Supplemental upper-bound estimates used the last plausible diagnosis date of May 8, based on the April 28 final study day, 4 days being earliest time from the onset to IgG detection and allowing PCR detection up to 14 days after the onset \[[@bib8]\].

Results {#sec3}
=======

Across NYS, a total of 15,626 adult residents with complete data were tested, of whom 15,101 (96.6%) had suitable specimens, of which 1887 (12.5%) were reactive and 340 (2.3%) indeterminate. After weighting, 12.5% were estimated reactive and after further adjustment for test characteristics, estimated cumulative incidence was 14.0% (95% CI: 13.3%--14.7%), corresponding to 2,139,300 (95% CI: 2,035,800--2,242,800) infection-experienced adults in NYS through approximately March 29 ([Table 1](#tbl1){ref-type="table"} ). In sensitivity analyses at the extremes of test characteristics, the cumulative incidence ranged from 9.8% (95% CI: \[9.1%--10.5%\]) to 15.0% (95% CI: \[14.3%--15.7%\]), representing a total of 1,494,700 (95% CI: \[1,391,800--1,597,600\]) to 2,286,600 (95% CI: \[2,178,200--2,395,100\]) adults in NYS ([Table 6](#tbls6){ref-type="table"}, [Table 7](#tbls7){ref-type="table"}).Table 1Reactivity and test characteristic--adjusted cumulative incidence of COVID-19, overall and by demographic factors and regionStratum% Of adults in New YorkReactivityTest characteristic--adjusted estimated cumulative incidence*P*-valueUnweighted \# reactive/Total sampleWeighted percent% (95% CI)Infection-experienced adults[∗](#tbl1fnlowast){ref-type="table-fn"} (95% CI)% Of infection-experienced adultsOverall100.01887/15,10112.514.0 (13.3--14.7)2,139,300 (2,035,800--2,242,800)100.0Sex.03 Male47.6918/663513.214.8 (13.8--15.8)1,076,500 (1,001,900--1,151,100)50.3 Female52.4969/846611.913.3 (12.4--14.2)1,062,200 (990,500--1,133,800)49.7Race and ethnicity\<.0001 Hispanic or Latino17.4757/273525.829.2 (27.2--31.2)775,800 (722,700--829,000)36.6 Non-Hispanic white58.0623/95457.38.1 (7.4--8.7)715,400 (657,100--773,700)33.7 Non-Hispanic black/African American13.9388/191318.020.2 (18.1--22.3)428,000 (382,700--473,400)20.2 Non-Hispanic Asian8.675/62911.112.4 (9.4--15.4)161,700 (122,600--200,800)7.6 Multiracial/other2.144/27910.711.9 (6.4--17.5)38,800 (20,800--56,800)1.8Age group (y).0002 18--3430.7377/315113.014.6 (13.1--16.1)682,600 (612,000--753,200)31.8 35--4415.9334/262813.715.3 (13.7--17.0)371,800 (331,700--411,900)17.3 45--5417.4479/334514.316.0 (14.6--17.5)424,700 (386,400--463,100)19.8 55+36.1697/597710.912.1 (11.2--13.1)667,800 (615,600--719,900)31.1Region\<.0001 New York City [†](#tbl1fndagger){ref-type="table-fn"}43.31319/594620.222.7 (21.5--24.0)1,504,400 (1,421,300--1,587,500)70.1 Westchester/Rockland Counties6.4134/98014.416.1 (13.2--19.0)156,500 (128,400--184,600)7.3 Long Island [‡](#tbl1fnddagger){ref-type="table-fn"}14.4241/207411.913.2 (11.4--15.1)291,800 (250,600--332,900)13.6 Rest of NYS [§](#tbl1fnsection){ref-type="table-fn"}35.9193/61013.43.6 (3.0--4.1)194,600 (162,600--226,600)9.1[^1][^2][^3][^4]

The cumulative incidence was higher among males (14.8%, 95% CI: \[13.8%--15.8%\]) than females (13.3%, 95% CI: \[12.4%--14.2%\], *P* = .03), with males comprising 50.3% of adult infections. This differed significantly by race and ethnicity, with Hispanic/Latino (29.2%, 95% CI: 27.2%--31.2%), non-Hispanic black/African American (20.2% \[95% CI, 18.1%--22.3%\]), and non-Hispanic Asian (12.4%, 95% CI: \[9.4%--15.4%\]) adults having higher cumulative incidence than non-Hispanic white adults (8.1%, 95% CI: \[7.4%--8.7%\], *P* \< .0001). Given these differences, Hispanics comprised the plurality (36.6%) of infection-experienced adults. Significant differences were also observed by age (*P* = .0002), ranging from highest levels among persons 45--54 years old (16.0%, 95% CI: \[14.6%--17.5%\]) to lowest among persons aged 55 years or older (12.1% \[95% CI: 11.2%--13.1%\]).

We observed regional heterogeneity in cumulative incidence, ranging from 22.7% (95% CI: 21.5%--24.0%) in NYC residents, to 16.1% (95% CI: 13.2%--19.0%) and 13.2% (11.4%--15.1%) in the respective metropolitan areas of Westchester/Rockland Counties and Long Island, to 3.6% (95% CI: \[3.0--4.1\]) in ROS (*P* \< .0001). Demographic patterns were heterogenous by region ([Table 2](#tbl2){ref-type="table"} ). Males had significantly higher cumulative incidence in all regions outside of, but not within, NYC. The patterns of racial disparity observed statewide were similar and statistically significant within NYC, Westchester/Rockland, and Long Island, but not in ROS. In each of the former 3 regions, Hispanic/Latino persons represented greater than 37% of infection-experienced adults, whereas in the latter non-Hispanic whites comprised a majority of infection-experienced adults (79.4%).Table 2Reactivity and test characteristic--adjusted cumulative incidence of COVID-19, demographic factors within the regionStratum% Of adults in regionReactivityTest characteristic--adjusted estimated cumulative incidence*P*-valueUnweighted \# reactive/Total sample[∗](#tbl2fnlowast){ref-type="table-fn"}Weighted percent% (95% CI)Infection-experienced adults[†](#tbl2fndagger){ref-type="table-fn"} (95% CI)% Of infection-experienced adults in regionNew York City [‡](#tbl2fnddagger){ref-type="table-fn"}Sex.26 Male46.7629/272720.923.5 (21.6--25.4)726,300 (668,500--784,100)48.3 Female53.3690/321919.622.1 (20.4--23.7)778,000 (718,300--837,600)51.7Race and ethnicity\<.0001 Hispanic or Latino27.4624/210329.233.0 (30.6--35.4)599,900 (556,800--643,000)39.8 Non-Hispanic white33.8264/175814.816.6 (14.6--18.5)371,300 (327,800--414,800)24.6 Non-Hispanic black/African American21.7329/139222.425.2 (22.5--27.9)361,700 (322,900--400,500)24.0 Non-Hispanic Asian14.568/50913.014.5 (11.0--18.0)139,000 (105,400--172,700)9.2 Multiracial/other2.534/18418.220.4 (13.7--27.2)34,400 (23,100--45,700)2.3Age group (y).04 18--3434.0252/125719.321.8 (19.2--24.4)490,200 (432,200--548,300)32.5 35--4417.4243/114420.823.4 (20.6--26.2)270,400 (238,100--302,700)18.0 45--5416.3334/132823.526.5 (23.8--29.2)286,700 (257,700--315,700)19.0 55+32.2490/221719.121.5 (19.6--23.5)459,000 (417,700--500,300)30.5Westchester/RocklandSex.049 Male47.672/45017.119.2 (14.6--23.8)88,700 (67,400--109,900)56.7 Female52.462/53011.913.3 (9.8--16.9)67,800 (49,600--85,900)43.3Race and ethnicity.0008 Hispanic or Latino21.037/14125.328.6 (20.2--37.0)58,300 (41,200--75,400)37.8 Non-Hispanic white57.962/6549.710.8 (8.0--13.5)60,400 (45,200--75,600)39.1 Non-Hispanic black/African American13.332/15220.122.7 (15.0--30.3)29,200 (19,400--39,000)18.9 Non-Hispanic Asian6.3∗∗7.78.5 (0--25.1)5200 (0--15,300)3.4 Multiracial/other1.6∗∗7.17.8 (0--19.4)1200 (0--2900)0.8Age group (y).78 18--3426.829/18416.118 (11.8--24.3)46,900 (30,600--63,200)29.9 35--4416.322/15615.217 (9.3--24.8)27,000 (14,700--39,200)17.2 45--5418.933/24714.516.2 (10.7--21.8)29,800 (19,600--40,000)19.0 55+37.950/39312.914.4 (10.0--18.9)53,100 (36,700--69,400)33.9Long Island [§](#tbl2fnsection){ref-type="table-fn"}Sex.15 Male48.3122/91313.114.7 (11.7--17.6)156,100 (125,100--187,100)53.5 Female51.7119/116110.711.9 (9.5--14.3)135,700 (108,700--162,600)46.5Race and ethnicity\<.0001 Hispanic or Latino15.989/30128.332.0 (26.1--37.9)112,100 (91,400--132,900)38.4 Non-Hispanic white67.3126/15997.98.7 (7.2--10.3)129,500 (106,800--152,200)44.4 Non-Hispanic black/African American8.816/11114.115.8 (6.6--25.0)30,800 (12,900--48,700)10.6 Non-Hispanic Asian6.3∗∗7.78.4 (0--18.7)11,800 (0--26,200)4.0 Multiracial/other1.7∗∗18.420.7 (3.9--37.5)7600 (1400--13,800)2.6Age group (y).73 18--3426.345/42912.614.1 (9.2--19.0)81,800 (53,500--110,000)28.0 35--4415.540/31712.413.8 (9.6--18.1)47,300 (32,800--61,800)16.2 45--5419.561/46812.814.3 (10.5--18.0)61,200 (45,100--77,300)20.9 55+38.795/86010.712.0 (9.5--14.4)102,200 (81,500--122,900)34.9Rest of New York State [‖](#tbl2fnverbar){ref-type="table-fn"}Sex.04 Male48.595/25453.94.2 (3.2--5.1)111,200 (85,800--136,600)57.3 Female51.598/35562.82.9 (2.3--3.6)83,100 (63,800--102,300)42.7Race and ethnicity.90 Hispanic or Latino5.2∗∗4.44.7 (0.8--8.7)13,600 (2300--24,900)7.0 Non-Hispanic white83.6171/55343.23.4 (2.8--3.9)154,300 (128,800--179,800)79.4 Non-Hispanic black/African American6.611/2584.04.3 (1.4--7.1)15,500 (5100--25,800)8.0 Non-Hispanic Asian2.7∗∗4.04.3 (0--9.4)6300 (0--13,900)3.2 Multiracial/other1.9∗∗4.24.5 (0--13.6)4700 (0--14,300)2.4Age group (y).04 18--3429.051/12814.14.3 (3.0--5.7)69,100 (47,500--90,700)35.2 35--4414.229/10113.53.8 (2.1--5.4)29,100 (16,300--41,900)14.8 45--5417.551/13024.34.6 (3.2--6.0)43,900 (30,500--57,400)22.4 55+39.362/25072.52.5 (1.8--3.2)54,000 (39,100--68,900)27.5[^5][^6][^7][^8][^9]

An estimated 8.9% (95% CI: 8.4%--9.3%) of infections in NYS were diagnosed as of April 9, 2020 ([Table 3](#tbl3){ref-type="table"} ). Males (9.4%, 95% CI: 8.8%--10.1%) had higher diagnosis levels than females (8.2%, 95% CI: 7.7%--8.8%). Those aged 55 years or older were most likely to be diagnosed (11.3%, 95% CI: 10.4%--12.2%). Diagnosis rates in NYC (7.1%, 95% CI: 6.7%--7.5%) and ROS (7.5%, 95% CI: 6.4%--8.9%) were about half those observed in the other regions. Considering the May 8 upper bound for diagnoses, a maximum of 15.7% (95% CI: 15.0%--16.5%) of overall infections could have been diagnosed, with similar patterns observed across levels of each factor ([Supplementary Table 8](#tbls8){ref-type="table"}).Table 3Estimated percentage of SARS-CoV-2 infections diagnosed[∗](#tbl3fnlowast){ref-type="table-fn"}StratumEstimated infection-experienced adultsDiagnosed adults through April 9, 2020% Of diagnosed adultsAdults (95% CI)Diagnoses% Diagnosed (95% CI)Overall2,139,300 (2,035,800--2,242,800)189,3838.9 (8.4--9.3)100.0Sex Male1,076,500 (1,001,900--1,151,100)101,0309.4 (8.8--10.1)53.7 Female1,062,200 (990,500--1,133,800)87,1968.2 (7.7--8.8)46.3 Unknown1157Age (y) 18--34682,600 (612,000--753,200)41,3356.1 (5.5--6.8)22.4 35--44371,800 (331,700--411,900)32,8458.8 (8.0--9.9)17.8 45--54424,700 (386,400--463,100)35,3078.3 (7.6--9.1)19.1 55+667,800 (615,600--719,900)75,12411.3 (10.4--12.2)40.7 Missing/invalid491Region New York City [†](#tbl3fndagger){ref-type="table-fn"}1,504,400 (1,421,300--1,587,500)106,4017.1 (6.7--7.5)56.2 Westchester/Rockland counties156,500 (128,400--184,600)23,55715.1 (12.8--18.3)12.4 Long Island [‡](#tbl3fnddagger){ref-type="table-fn"}291,800 (250,600--332,900)44,90715.4 (13.5--17.9)23.7 Rest of State [§](#tbl3fnsection){ref-type="table-fn"}194,600 (162,600--226,600)14,5187.5 (6.4--8.9)7.7[^10][^11][^12][^13]

Discussion {#sec4}
==========

From the largest U.S. SARS-CoV-2 serosurvey to date, we estimated that over 2 million adult NYS residents were infected through the end of March. Our findings estimate the extent of transmission of and community experience with SARS-CoV-2, particularly in the NYC metropolitan region. Despite large numbers of persons acquiring SARS-CoV-2, this represents only 14.0% of adult residents, suggesting that, even in this COVID-19 epicenter, the epidemic is substantially less than the estimated \~70% U.S. herd immunity threshold \[[@bib25]\]. Against this remaining epidemic potential, ongoing vigilance through rigorous and extensive epidemic monitoring, testing, and contact tracing is a necessary component for predicting, preventing, and/or mitigating a second epidemic wave, consistent with state and federal guidance for reopening \[[@bib5],[@bib26]\]. This vigilance is needed even in the rest of NYS outside the metropolitan region, which are in the first phases of reopening in NYS, and where lowest cumulative incidence suggests the highest proportion susceptible.

Our finding of higher cumulative incidence in the regions of the NYC metropolitan area, particularly NYC, is consistent with the known distribution of diagnoses. Furthermore, in these regions of high urbanicity, significant racial/ethnic disparities in infection history were found, with minority communities experiencing disproportionate risk. The drivers of greater COVID-19 risk and disparities in urban areas continue to be studied, but may relate to population density and the mechanisms by which transportation, employment, housing, and other socioeconomic or environmental factors shape opportunities for transmission \[[@bib27], [@bib28], [@bib29]\]. A recent NYS study on a random sample of COVID-19 hospitalizations showed limited racial/ethnic differences in clinical outcomes, suggesting that observed differences in mortality by race and ethnicity may be in large part driven by different infection histories in the community \[[@bib3],[@bib30], [@bib31], [@bib32]\]. Research is needed to understand the drivers of increased COVID-19 risk experienced by minority communities, followed by actions to improve health equity.

The finding that over 8.9% of adults were diagnosed reveals both the opportunities for further expansion of diagnostic testing in NYS, yet in the context of far higher diagnosis and testing levels than other U.S. settings suggests substantial progress to date \[[@bib1],[@bib13]\]. Compared to all persons with infection history, there was a higher representation of males and those older than 55 years among diagnosed persons. Given the lower reactivity rates observed among this age group, our results expand observations from previous studies that older adults may be more likely to exhibit symptoms or illness or be more likely to seek care \[[@bib30],[@bib33], [@bib34], [@bib35]\].

Although not an aim of this analysis, we note that in conjunction with 12,822 publicly reported COVID-19 deaths for NYS through April 17 (reflecting median 19 days-post-infection to death), our findings suggest an infection fatality ratio of 0.6%. This estimate is in line with estimates of 0.5%--1.0% observed in other countries; however, additional analyses are needed to more precisely estimate the infection fatality ratio in NYS \[[@bib36],[@bib37]\].

Strengths of our study include a large sample, which contained 0.1% of the adult NYS population, and a systematic sampling approach in one of the only open public venues in the state, where a necessary commodity is purchased. Although a convenience sample, survey weights adjusted for biased demographic/geographic representation, noting that the general agreement of unweighted and weighted results suggests demographic representativeness of the study sample, and we further adjusted results for assay performance, under varied scenarios. Our study may nevertheless be limited by residual nonrepresentativeness of the underlying population. This includes potential undersampling of persons from vulnerable groups who might be less likely to go grocery shopping. For this to impact our findings, those remaining home would need to have differential antibody prevalence compared with their age/sex/racial-ethnic/regional group peers. If persons staying at home had lower prevalence because of self-isolation, our study\'s cumulative incidence would be a slight overestimate. Furthermore, our sample did not include those who have died from COVID-19 or those who reside in long-term care facilities, which have been differentially impacted, causing a slight underestimate, nor those in the hospital or at home due to COVID-19 illness, some of whom would be expected to have detectable antibodies \[[@bib38],[@bib39]\]. Such actively symptomatic persons would be expected to be a small portion of the cumulative infection burden since the outbreak\'s commencement, and given most would have been infected after March 29, their exclusion also likely causes observed values to be overestimated.

Although data are limited on the potential for self-selection to alter our results, a recent Icelandic study found comparable prevalence when participants were tested after online self-registration versus random invitation \[[@bib16]\]. This finding, in conjunction with our systematic community intercept approach, suggests that this bias may be small, outside of outright nonresponse. We note that although every effort was made to ensure unbiased sampling through a DOH staff-led recruitment process, patron-initiated requests for testing were honored, and in some sites, accounted for a significant percentage of total tests performed. It is possible that customers who seek out testing may be more likely to have been exposed to SARS-CoV-2. If true, our estimate of cumulative incidence would be overestimated. Another source of potential recruitment bias comes from patron refusal to be tested, either on initial request or after agreeing to participate. Although not systematically collected, nightly report outs by testing leads indicated that most persons approached agreed to be tested and that few persons left after agreeing to be tested, regardless of wait time, supporting low nonresponse. Results presented may differ from publicly discussed preliminary estimates, given both our inclusion of more participants and analytic adjustments for test characteristics. Timeframes used for cumulative infections and diagnoses are approximate, being based on the evolving SARS-CoV-2 immunological and testing literature, with the 10-day sampling period during a linear growth phase of the epidemic.

The findings of this study suggest extensive SARS-CoV-2 transmission in NYS and highlight the remaining opportunities for prevention and diagnosis. As the epidemic grows in other regions of the country, this study offers a potential model for other jurisdictions to monitor their epidemic. Estimates of cumulative incidence can be combined with diagnostic totals, or other epidemic markers such as mortality, to provide a holistic epidemic view during a time of unprecedented pandemic and to best craft high-impact approaches to prevention, containment, treatment, and mitigation.

Appendix {#appsec1}
========

Validation studies {#appsec1.1}
------------------

### Part 1. Assay specificity {#appsec1.1.1}

Table 1Cutoff assay using normal human dry blood spotsAssayNumber testedNumber \> mean + 3 SDsNumber \> mean + 6 SDsSpecificity95% CISARS-CoV-1N19651195/196 = 99.5%98.5%--100%SARS-CoV-2N922092/92 = 100%96.1%--100%[^14]Table 2Serum collected from patients with antibodies to the indicated nonrespiratory agents tested for reactivity to the SARS-CoV-1N proteinAnalyteNumber testedNumber \> mean + 3 SDsNumber \>mean + 6 SDsAntinuclear antibodies300Chikungunya virus300Dengue virus300Enterovirus200Epstein Barr Virus300Hepatitis C virus300Herpes Simplex virus300HIV300Measles600Mumps600Parvovirus B19400Rheumatoid factor300Rubella300Syphilis311Varicella Zoster virus300West Nile virus300Zika virus300TOTAL5711Table 3Serum collected from patients diagnosed with the indicated non--COVID-19 respiratory agents tested for reactivity to the SARS-CoV-1N and SARS-CoV-2N proteinAnalyteSARS-CoV-1NSARS-CoV-2NNumber testedNumber \> mean + 3 SDsNumber \> mean + 6 SDsNumber testedNumber \> mean + 3 SDsNumber \> mean + 6 SDsHuman coronavirus NL63600400Human coronavirus OC43200200Human parainfluenza virus100100Influenza6001510Metapneumovirus600600Rhinovirus700600Total28003410

### Part 2. Assay sensitivity {#appsec1.1.2}

Table 4SARS-CoV-2N assay results for a set of 232 individuals with self-reported positive PCR results, with median (IQR) days from the symptom onset to DBS collectionResult\#Median days after the symptom onsetIQRNonreactive213328--37Indeterminate73028--34Reactive2043530--40Total232[^15]

### Part 3 -- SARS-CoV-1N versus SARS-CoV-2N assay comparison {#appsec1.1.3}

Fig. 1Comparison of MFI values for DBS samples tested by the SARS-CoV-1N versus SARS-CoV-2N assay.Table 5Comparison of qualitative results of the same samples tested by the SARS-CoV-1N versus SARS-CoV-2N assayResultSARS-CoV-2NRINDNRTotalSARS-CoV-1NR170017IND0000NR56145156TOTAL226145173Concordance162/17394%Results match exactly (NR-NR, IND-IND, R-R)Discordance5/1733%Reactive = Nonreactive, Nonreactive = Reactive[^16]

Sensitivity analyses for cumulative incidence and percent diagnosed {#appsec1.2}
-------------------------------------------------------------------

Table 6Reactivity and test characteristic--adjusted cumulative incidence of COVID-19, overall and by demographic factors and region: sensitivity 92.1% and specificity 96.1%StratumReactivityTest characteristic--adjusted estimated cumulative incidenceUnweighted \# reactive/Total sampleWeighted percent%(95% CI)Infection-experienced adults[∗](#tbls6fnlowast){ref-type="table-fn"}(95% CI)% Of infection-experienced adultsOverall1887/15,10112.59.8(9.1--10.5)1,494,700(1,391,800--1,597,600)100.0Sex Male918/663513.210.6(9.6--11.6)769,200(695,000--843,400)51.5% Female969/846611.99.1(8.2--10.0)724,900(653,700--796,200)48.5%Race/ethnicity Hispanic or Latino757/273525.824.9(22.9--26.9)661,300(608,400--714,100)24.9 NH-white623/95457.33.9(3.2--4.5)344,500(286,500--402,500)3.9 NH-black/African American388/191318.015.9(13.8--18.1)337,800(292,700--382,900)15.9 NH-Asian75/62911.18.2(5.2--11.1)106,600(67,800--145,500)8.2 NH-Multiracial/other44/27910.77.7(2.2--13.2)25,100(7300--43,000)7.7Age group (y) 18--34377/315113.010.4(8.9--11.9)484,900(414,700--555,100)10.4 35--44334/262813.711.1(9.4--12.7)269,100(229,200--308,900)11.1 45--54479/334514.311.8(10.3--13.2)312,500(274,300--350,600)11.8 55+697/597710.97.9(7.0--8.9)435,900(384,000--487,800)7.9Region New York City [†](#tbls6fndagger){ref-type="table-fn"}1319/594620.218.5(17.2--19.7)1,221,700(1,139,100--1,304,300)∗∗ Westchester/Rockland Counties134/98014.411.9(9.0--14.8)115,400(87,500--143,400)∗∗ Long Island [‡](#tbls6fnddagger){ref-type="table-fn"}241/207411.99.0(7.2--10.9)198,800(157,900--239,700)∗∗ Rest of NYS [§](#tbls6fnSection){ref-type="table-fn"}^,^[‖](#tbls6fnverbar){ref-type="table-fn"}193/61013.4∗∗∗∗∗∗∗∗∗∗[^17][^18][^19][^20][^21]Table 7Reactivity and test characteristic--adjusted cumulative incidence of COVID-19, overall and by demographic factors and region: sensitivity 83.7% and specificity 100%StratumReactivityTest characteristic--adjusted estimated cumulative incidenceUnweighted \# reactive/Total sampleWeighted percent% (95% CI)Infection-experienced adults [∗](#tbls7fnlowast){ref-type="table-fn"} (95% CI)% Of infection-experienced adultsOverall1887/15,10112.515.0 (14.3--15.7)2,286,600 (2,178,200--2,395,100)100.0Sex Male918/663513.215.8 (14.7--16.9)1,149,500 (1,071,300--1,227,600)50.3 Female969/846611.914.2 (13.3--15.2)1,136,600 (1,061,500--1,211,700)49.7Race/ethnicity Hispanic or Latino757/273525.830.9 (28.8--33.0)820,700 (765,000--876,400)36.2 NH-white623/95457.38.8 (8.1--9.4)775,900 (714,800--837,000)34.2 NH-black/African American388/191318.021.5 (19.2--23.7)454,700 (407,200--502,200)20.1 NH-Asian75/62911.113.3 (10.1--16.4)173,300 (132,300--214,300)7.6 NH-Multiracial/other44/27910.712.8 (7.0--18.6)41,600 (22,800--60,500)1.8Age group (y) 18--34377/315113.015.6 (14.0--17.2)729,100 (655,100--803,100)31.8 35--44334/262813.716.3 (14.6--18.1)396,700 (354,700--438,700)17.3 45--54479/334514.317.1 (15.6--18.6)452,800 (412,700--493,000)19.7 55+697/597710.913.0 (12.0--14.0)716,000 (661,300--770,600)31.2Region New York City [†](#tbls7fndagger){ref-type="table-fn"}1319/594620.224.1 (22.8--25.4)1,595,700 (1,508,700--1,682,800)69.5 Westchester/Rockland Counties134/98014.417.2 (14.2--20.2)166,800 (137,400--196,300)7.3 Long Island [‡](#tbls7fnddagger){ref-type="table-fn"}241/207411.914.2 (12.2--16.1)312,200 (269,100--355,400)13.6 Rest of NYS [§](#tbls7fnSection){ref-type="table-fn"}193/61013.44.0 (3.4--4.6)220,200 (186,700--253,700)9.6[^22][^23][^24][^25]Table 8Estimated percentage of SARS-COV-2 infections diagnosed by the last plausible diagnosis dateEstimated infection-experienced adultsDiagnosed adults through May 8, 2020Adults 95% CIDiagnoses% diagnosed (95% CI)% of diagnosed adultsOverall2,139,300 (203,5800--2,242,800)335,77015.7 (15.0--16.5)100.0Sex Male1,076,500 (1,001,900--1,151,100)172,23816.0 (15.0--17.2)51.6 Female1,062,200 (990,500--1,133,800)161,79915.2 (14.3--16.3)48.4 Unknown1733Age (y) 18--34682,600 (612,000--753,200)71,42710.5 (9.5--11.7)21.9 35--44371,800 (331,700--411,900)54,79214.7 (13.3--16.5)16.8 45--54424,700 (386,400--463,100)61,05414.4 (13.2--15.8)18.8 55+667,800 (615,600--719,900)138,31220.7 (19.2--22.5)42.5 Missing/invalid851Region New York City [∗](#tbls8fnlowast){ref-type="table-fn"}1,504,400 (1,421,300--1,587,500)187,62312.5 (11.8--13.2)55.9 Westchester/Rockland Counties156,500 (128,400--184,600)39,96725.5 (21.7--31.1)11.9 Long Island [†](#tbls8fndagger){ref-type="table-fn"}291,800 (250,600--332,900)75,10025.7 (22.6--30.0)22.4 Rest of State [‡](#tbls8fnddagger){ref-type="table-fn"}194,600 (162,600--226,600)33,08017.0 (14.6--20.3)9.9[^26][^27][^28]
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[^1]: Stratified estimates may not exactly sum to total because of rounding and differences between the weighting scheme and noninstitutionalized population totals.

[^2]: Boroughs of Bronx, Brooklyn, Manhattan, Queens, Staten Island.

[^3]: Nassau and Suffolk Counties.

[^4]: Albany, Allegany, Broome, Cattaraugus, Cayuga, Chautauqua, Chemung, Chenango, Clinton, Columbia, Cortland, Delaware, Dutchess, Erie, Essex, Franklin, Fulton, Genesee, Greene, Hamilton, Herkimer, Jefferson, Lewis, Livingston, Madison, Monroe, Montgomery, Niagara, Oneida, Onondaga, Ontario, Orange, Orleans, Oswego, Otsego, Putnam, Rensselaer, St. Lawrence, Saratoga, Schenectady, Schoharie, Schuyler, Seneca, Steuben, Sullivan, Tioga, Tompkins, Ulster, Warren, Washington, Wayne, Wyoming, and Yates counties.

[^5]: Unweighted results with numerator \< 10 are suppressed to protect participant confidentiality, indicated by ∗∗.

[^6]: Stratified estimates may not exactly sum to total because of rounding and differences between the weighting scheme and noninstitutionalized population totals.

[^7]: Boroughs of Bronx, Brooklyn, Manhattan, Queens, Staten Island.

[^8]: Nassau and Suffolk Counties.

[^9]: Albany, Allegany, Broome, Cattaraugus, Cayuga, Chautauqua, Chemung, Chenango, Clinton, Columbia, Cortland, Delaware, Dutchess, Erie, Essex, Franklin, Fulton, Genesee, Greene, Hamilton, Herkimer, Jefferson, Lewis, Livingston, Madison, Monroe, Montgomery, Niagara, Oneida, Onondaga, Ontario, Orange, Orleans, Oswego, Otsego, Putnam, Rensselaer, St. Lawrence, Saratoga, Schenectady, Schoharie, Schuyler, Seneca, Steuben, Sullivan, Tioga, Tompkins, Ulster, Warren, Washington, Wayne, Wyoming, and Yates counties.

[^10]: Complete statewide data on the case race and ethnicity are not currently available.

[^11]: Boroughs of Bronx, Brooklyn, Manhattan, Queens, Staten Island.

[^12]: Nassau and Suffolk Counties.

[^13]: Albany, Allegany, Broome, Cattaraugus, Cayuga, Chautauqua, Chemung, Chenango, Clinton, Columbia, Cortland, Delaware, Dutchess, Erie, Essex, Franklin, Fulton, Genesee, Greene, Hamilton, Herkimer, Jefferson, Lewis, Livingston, Madison, Monroe, Montgomery, Niagara, Oneida, Onondaga, Ontario, Orange, Orleans, Oswego, Otsego, Putnam, Rensselaer, St. Lawrence, Saratoga, Schenectady, Schoharie, Schuyler, Seneca, Steuben, Sullivan, Tioga, Tompkins, Ulster, Warren, Washington, Wayne, Wyoming, and Yates counties.

[^14]: Normal DBS collected before December 2019 were tested to establish background levels of reactivity to the SARS-CoV-1N and SARS-CoV-2N proteins. Specificity for primary analyses was based on the mean of observed reactivity to each protein (99.5% and 100%, respectively), which was 99.75%.

[^15]: Based on 204 of 232 reactive, estimate sensitivity was 87.9% (exact 95% CI: \[83.7--92.1%\]).

[^16]: Kappa of 0.855 (95% CI: 0.731--0.979), as measured on the 2 × 2 table excluding IND results, indicates strong agreement above chance.

[^17]: Stratified estimates may not exactly sum to total because of rounding and differences between the weighting scheme and noninstitutionalized population totals.

[^18]: Boroughs of Bronx, Brooklyn, Manhattan, Queens, Staten Island.

[^19]: Nassau and Suffolk Counties.

[^20]: Albany, Allegany, Broome, Cattaraugus, Cayuga, Chautauqua, Chemung, Chenango, Clinton, Columbia, Cortland, Delaware, Dutchess, Erie, Essex, Franklin, Fulton, Genesee, Greene, Hamilton, Herkimer, Jefferson, Lewis, Livingston, Madison, Monroe, Montgomery, Niagara, Oneida, Onondaga, Ontario, Orange, Orleans, Oswego, Otsego, Putnam, Rensselaer, St. Lawrence, Saratoga, Schenectady, Schoharie, Schuyler, Seneca, Steuben, Sullivan, Tioga, Tompkins, Ulster, Warren, Washington, Wayne, Wyoming, and Yates counties.

[^21]: Estimated values for Rest of NYS are negative because of antibody prevalence \<1---specificity (observed results may be dominated by false positives). True cumulative incidence is greater than 0, as evidence by diagnosed cases, rendering study-based cumulative incidence inestimable under these test characteristics. Values that cannot be estimated are indicated with ∗∗ in the table.

[^22]: Stratified estimates may not exactly sum to total because of rounding and differences between the weighting scheme and noninstitutionalized population totals.

[^23]: Boroughs of Bronx, Brooklyn, Manhattan, Queens, Staten Island.

[^24]: Nassau and Suffolk Counties.

[^25]: Albany, Allegany, Broome, Cattaraugus, Cayuga, Chautauqua, Chemung, Chenango, Clinton, Columbia, Cortland, Delaware, Dutchess, Erie, Essex, Franklin, Fulton, Genesee, Greene, Hamilton, Herkimer, Jefferson, Lewis, Livingston, Madison, Monroe, Montgomery, Niagara, Oneida, Onondaga, Ontario, Orange, Orleans, Oswego, Otsego, Putnam, Rensselaer, St. Lawrence, Saratoga, Schenectady, Schoharie, Schuyler, Seneca, Steuben, Sullivan, Tioga, Tompkins, Ulster, Warren, Washington, Wayne, Wyoming, and Yates counties.

[^26]: Boroughs of Bronx, Brooklyn, Manhattan, Queens, Staten Island.

[^27]: Nassau and Suffolk Counties.

[^28]: Albany, Allegany, Broome, Cattaraugus, Cayuga, Chautauqua, Chemung, Chenango, Clinton, Columbia, Cortland, Delaware, Dutchess, Erie, Essex, Franklin, Fulton, Genesee, Greene, Hamilton, Herkimer, Jefferson, Lewis, Livingston, Madison, Monroe, Montgomery, Niagara, Oneida, Onondaga, Ontario, Orange, Orleans, Oswego, Otsego, Putnam, Rensselaer, St. Lawrence, Saratoga, Schenectady, Schoharie, Schuyler, Seneca, Steuben, Sullivan, Tioga, Tompkins, Ulster, Warren, Washington, Wayne, Wyoming, Yates counties.
